Hanmi Pharm’s ‘Olita’ accepted health insurance benefits even with liquid biopsy, soon to be decided
The range of health insurance benefits for ‘Olita,’ a Hanmi Pharm’s 3rd generation new drug for the treatment of non-small cell lung cancer, is expected to be extended to liquid biopsy patients.
According to the pharmaceutical industry on the 29th, the Health Insurance Review & Assessment Servic...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
